Nephritis and nephrotic syndrome

Japanese Journal of Nephrology

Volumn 55, Issue 1, 2013, Pages 35-41

  Kaneko, Yoshikatsu ^a   Narita, Ichiei ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; NEPHRITIS; NEPHROTIC SYNDROME;

ANIMALS; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; NEPHROTIC SYNDROME; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 84874136007     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis - a new look at an old entity. N Engl J Med 2012; 366: 1119-1131.
2. D'Agati VD, Bomback AS. C3 glomerulopathy: what's in a name? Kidney Int 2012; 82: 379-381.
3. Sethi S, Nester CM, Smith RJH. Membranoproliferative glomerulonephritis and C3 glomerulopahy: resolving the confusion. Kidney Int 2012; 81: 434-441.
4. Fakhouri F, Frémeaux-Bacchi V, Noel LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6: 494-499.
5. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJH. C3 glomerulonephritis: clini-copathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82: 465-473.
6. Servais A, Noël LH, Roumenina LT, Quintrec ML, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Griinfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464.
7. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternative-day prednisone: a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992; 6: 123-130.
8. Idiopathic membranoproliferative glomerulonephritis. Kidney Int 2012; 2(Suppl): 198-199.
9. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types and II in children and adults and long-term prognosis. Am J Med 1983: 74: 175-192.
10. West CD. Idiopathic membranoproliferative glomerulonephritis in childhood. Pediatr Nephrol 1992; 6: 96-103.
11. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012; 366: 1163-1165.
12. Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, Pluthero F, Licht C. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366: 1165-1166.
13. Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552-559.
14. Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6: 1488-1494.
15. Lapeyraque AL, Frdmeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 621-624.
16. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-546.
17. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Her-litz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756.
18. Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D'Agati VD. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23: 1229-1237.
19. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuira. Nat Biotechnol 2007; 25: 1256-1264.
20. 2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21.
21. 2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1735-1743.
22. Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fech-ner K, Helmchen U, Stahl RAK. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011: 26: 2526-2532.
23. 2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1137-1143.
24. Debiec H, Ronco P. PLA2R antoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011 1364: 689-690.
25. 2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012; 82: 797-804.
26. Polanco N, Gutiérrez E, Covarsf A, Ariza F, Carrefio A, Vigil A, Baltar J, Fernandez-Fresnedo G, Martin C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, FernSndez-JuaYez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernandez-Vega F, Praga M. Grupo de Estudio de las Enferme-dades Glomerulares de la Sociedad Espafiola de Nefrologfa: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010 21: 697-704.
27. Waldman M, Austin HA III. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1617-1630.
28. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923-924.
29. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasa M, Remuzzi G. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1416-1425.
30. Maeda I, Hayashi T, Kogawa-Sato K, Okumoto-Shibata M, Hamada M, Kishida M, Kitabayashi C, Morikawa T, Okada N, Okumura M, Konishi M, Konishi Y, Endo G, Imanishi M. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transplant 2012; 27: 2806-2813.
31. Barratt J, Smith AC, Molyneux K, Feehally J. Immunopatho-genesis of IgAN. Semin Immunopathol 2007; 29: 427-443.
32. Barratt J, Eitner F, Feehaly J, Floege J. Immune complex formation in IgA nephropathy: a case of the 'right' antibodies in the 'wrong' place at the 'wrong' time? Nephrol Dial Transplant 2009; 24: 3620-3623.
33. Cox SN, Sallustio F, Serino G, Loverre A, Pesce F, Gigante M, Zaza G, Stifanelli PF, Ancona N, Schena FP. Activated innate imunity and the involvement of CX3CRl-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int 2012; 82: 548-560.
34. Cockwell P, Chakravorty SJ, Girdlestone J, Savage COS. Frac-talkine expression in human renal inflammation. J Pathol 2002; 196: 85-90.
35. Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int 2002; 62: 488-495.
36. Suzuki S, Suzuki Y, Yamanaka T, Hirose S, Nishimura H, Toei J, Horikoshi S, Tomino Y. Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23. J Am Soc Nephrol 2005; 16: 1289-1299.
37. Okazaki K, Suzuki Y, Otsuji M, Suzuki H, Kihara M, Kajiyama T, Hashimoto A, Nishimura H, Brown R, Hall S, Novak J, Izui S, Hirose S, Tomino Y. Development of a model of early-onset IgA nephropathy. J Am Soc Nephrol 2012; 23: 1364-1374.
38. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J. Aberrantly glycosylated IgAl in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119: 1668-1677.
39. Borza CM, Su Y, Chen X, Yu L, Mont S, Chetyrkin S, Voziyan P, Hudson BG, Billings PC, Jo H, Bennett JS, DeGrado WF, Eckes B, Zent R, Pozzi A. Inhibition of integrin α2βl ameliorates glomerular injury. J Am Soc Nephrol 2012; 23: 1027-1038.
40. Chen X, Moeckel G, Morrow JD, Cosgrove D, Harris RC, Fogo AB, Zent R, Pozzi A. Lack of integrin a α1β1 leads to severe glomerulosclerosis after glomerular injury. Am J Pathol 2004; 165: 617-630.
41. Kaneko Y, Otsuka T, Tsuchida Y, Gejyo F, Narita I. Integrin α1/βl and α2/βl as a receptor for IgAl in human glomerular mesangial cells in IgA nephropathy. Int Immunol 2012: 24: 219-232.